Lymphoma cell culture studies also showed that rituximab may suppress the constitutively active NF-κB pathway in the non-GC-type DLBCL via significantly upregulating RKIP expression, resulting in decreased activity of the NF-κB pathway and diminishing NF-κB DNA-binding activity [20] and further leading to the enhanced sensitivity of chemotherapy. The gene discussed is PEBP1; the disease is lymphoma.